Corvus Pharmaceuticals Raises $164.5M in Stock Offering, Extends Runway Amid Positive Soquelitinib Data

summarizeSummary

Corvus Pharmaceuticals announced a $164.5 million public offering of common stock, significantly extending its cash runway into Q1 2028, following positive Phase 1 clinical trial results for soquelitinib in atopic dermatitis.

check_boxKey Events

• Public Offering of Common Stock

  Corvus Pharmaceuticals is offering 7,900,677 shares of common stock at a price of $22.15 per share, generating approximately $164.5 million in net proceeds before expenses. Underwriters have an option to purchase an additional 1,185,101 shares.

• Extended Cash Runway

  The net proceeds from this offering, combined with existing cash, are expected to fund operations into the first quarter of 2028, addressing previous 'going concern' disclosures and providing crucial financial stability.

• Positive Soquelitinib Phase 1 Results

  The company announced positive results from cohort 4 of its randomized, blinded, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis, showing favorable safety and efficacy.

• Advancement to Phase 2 Trial

  Based on the encouraging Phase 1 data, Corvus Pharmaceuticals plans to initiate a Phase 2 trial for soquelitinib in patients with moderate to severe atopic dermatitis in the first quarter of 2026.

auto_awesomeAnalysis

Corvus Pharmaceuticals has successfully completed a significant public offering of 7,900,677 shares of common stock, raising approximately $164.5 million in net proceeds. This capital raise is critical as the company previously disclosed a 'going concern' risk, and this funding is expected to extend its cash runway into the first quarter of 2028. The offering was opportunistically timed following the announcement of positive Phase 1 clinical trial results for its lead product candidate, soquelitinib, in patients with moderate to severe atopic dermatitis. These positive clinical developments likely facilitated the successful capital raise, providing essential funding for ongoing and planned Phase 2 and Phase 3 clinical trials, and mitigating immediate liquidity concerns.